Crick
HomeTrialsGenesDrugs23andMeGraphBlogContact
  • Home
  • Trials
  • Genes
  • Drugs
  • 23andMe
  • Graph
  • Blog
  • Contact
Crick

An open-source clinical intelligence platform. Explore clinical trials, gene networks, and molecular structures using public data sources.

Data Sources

  • ClinicalTrials.gov
  • OpenTargets
  • ClinVar
  • PubChem

Links

  • Contact
  • About
  • Privacy

© 2026 Crick. All rights reserved.

Crick is for educational purposes only. Not medical advice.

Results for “Bortezomib”

916 trials

Filters

Phase
Early Phase 1
Phase 1
Phase 2
Phase 3
Phase 4
Status
Recruiting
Active, Not Recruiting
Not Yet Recruiting
Completed
Enrolling by Invitation

Showing 20 of 916 results

Testing effectiveness (Phase 2)Study completedNCT04173585
What this trial is testing

TEAM-Trial: Targeting Epigenetic Therapy Resistance in AML With Bortezomib

Who this might be right for
Acute Myeloid Leukemia
University Hospital Heidelberg 50
Testing effectiveness (Phase 2)Study completedNCT00777738
What this trial is testing

Efficacy of Bortezomib (Velcade(R)) in Patients With Advanced Waldenström Macroglobulinemia

Who this might be right for
Waldenstrom Macroglobulinemia
Assistance Publique - Hôpitaux de Paris 34
Testing effectiveness (Phase 2)Study completedNCT04445701
What this trial is testing

Study of AO-176 as Monotherapy and in Combination With Bortezomib/Dexamethasone in Relapsed/Refractory Multiple Myeloma

Who this might be right for
Multiple Myeloma
Arch Oncology 10
Testing effectiveness (Phase 2)Ended earlyNCT01729338
What this trial is testing

Velcade + Cyclophosphamide in Newly Diagnosed Multiple Myeloma

Who this might be right for
Multiple Myeloma
Duke University 17
Early research (Phase 1)Study completedNCT00505700
What this trial is testing

VELCADE in Combination With Idarubicin and Cytosine Arabinoside in Patients With Acute Myelogenous Leukemia

Who this might be right for
Leukemia
Massachusetts General Hospital 36
Testing effectiveness (Phase 2)Study completedNCT00547534
What this trial is testing

Pilot Study of Bortezomib, Bendamustine and Rituximab on Non-Hodgkin's Lymphoma

Who this might be right for
Non-Hodgkin's Lymphoma
University of Rochester 31
Testing effectiveness (Phase 2)Study completedNCT00381940
What this trial is testing

Bortezomib, Ifosfamide, and Vinorelbine Tartrate in Treating Young Patients With Hodgkin's Lymphoma That is Recurrent or Did Not Respond to Previous Therapy

Who this might be right for
Adult Lymphocyte Depletion Hodgkin LymphomaAdult Lymphocyte Predominant Hodgkin LymphomaAdult Mixed Cellularity Hodgkin Lymphoma+17 more
National Cancer Institute (NCI) 26
Testing effectiveness (Phase 2)Study completedNCT01083316
What this trial is testing

Bortezomib and Dexamethasone Followed by High-Dose Melphalan and Stem Cell Transplantation for Primary (AL) Amyloidosis

Who this might be right for
Amyloidosis
Boston Medical Center 35
Large-scale testing (Phase 3)Study completedNCT01241708
What this trial is testing

Tandem Auto Stem Cell Transplant With Melphalan Followed by Melphalan and Bortezomib in Patients With Multiple Myeloma

Who this might be right for
Multiple MyelomaAuto Stem Cell Transplant
Hackensack Meridian Health 148
Large-scale testing (Phase 3)Active Not RecruitingNCT04246047
What this trial is testing

Evaluation of Efficacy and Safety of Belantamab Mafodotin, Bortezomib and Dexamethasone Versus Daratumumab, Bortezomib and Dexamethasone in Participants With Relapsed/Refractory Multiple Myeloma

Who this might be right for
Multiple Myeloma
GlaxoSmithKline 494
Testing effectiveness (Phase 2)Study completedNCT00114738
What this trial is testing

EPOCH-R Chemotherapy Plus Bortezomib to Treat Mantle Cell Lymphoma

Who this might be right for
Lymphoma, Mantle CellMantle Cell Lymphoma
National Cancer Institute (NCI) 53
Testing effectiveness (Phase 2)Study completedNCT04083014
What this trial is testing

Single-dose Anti-CD20 Antibody With Bortezomib for Relapsed Refractory Autoimmune Hemolytic Anemia

Who this might be right for
Autoimmune Hemolytic AnemiaAutoimmune Hemolytic Anemia and Autoimmune Thrombocytopenia
Peking Union Medical College Hospital 33
Testing effectiveness (Phase 2)Study completedNCT00068289
What this trial is testing

Bortezomib in Treating Patients With Recurrent or Refractory Extensive-Stage Small Cell Lung Cancer Previously Treated With Platinum-Based Chemotherapy

Who this might be right for
Lung Cancer
SWOG Cancer Research Network
Testing effectiveness (Phase 2)Study completedNCT00436059
What this trial is testing

The Efficacy of Velcade on Bone Tissue During Myelomatosis (Bone Marrow Cancer)

Who this might be right for
Multiple Myeloma
Vejle Hospital 20
Not applicableStudy completedNCT02178579
What this trial is testing

Prospective Observation of Cardiac Safety With Proteasome Inhibition

Who this might be right for
Heart FailureMultiple Myeloma
Vanderbilt University Medical Center 95
Early research (Phase 1)Study completedNCT01174888
What this trial is testing

Phase I Combination of Midostaurin, Bortezomib, and Chemo in Relapsed/Refractory Acute Myeloid Leukemia

Who this might be right for
Acute Myeloid LeukemiaAcute Myeloid Leukemia With Multilineage Dysplasia FollowingMyelodysplastic Syndrome+8 more
Alison Walker 34
Testing effectiveness (Phase 2)Study completedNCT01323920
What this trial is testing

Bortezomib-based GVHD Prophylaxis After Allogeneic Transplant for Patients Without Matched Related Donors

Who this might be right for
LeukemiaLymphomaMyelodysplastic Syndrome
Dana-Farber Cancer Institute 35
Testing effectiveness (Phase 2)Ended earlyNCT02353468
What this trial is testing

Bortezomib, Lenalidomide, and Dexamethasone in Treating Patients With Multiple Myeloma Undergoing Stem Cell Transplant

Who this might be right for
Refractory Plasma Cell Myeloma
University of Colorado, Denver 3
Early research (Phase 1)Study completedNCT00310024
What this trial is testing

Vorinostat and Bortezomib in Treating Patients With Relapsed or Refractory Multiple Myeloma

Who this might be right for
Refractory Multiple MyelomaStage I Multiple MyelomaStage II Multiple Myeloma+1 more
National Cancer Institute (NCI) 40
Testing effectiveness (Phase 2)Study completedNCT00095680
What this trial is testing

Extension Study of the Efficacy and Safety of Oral SCIO-469 in Relapsed, Refractory Patients With Multiple Myeloma

Who this might be right for
Multiple Myeloma
Scios, Inc. 30
Load More Results